THE World Health Organization (WHO) awaits full clinical data on the antiviral drug prepared by Merck & Co Inc for the treatment of patients with mild to moderate symptoms of the disease caused by coronavirus, according to a statement from a representative of the organization today, one day after the announcement of the pharmaceutical company that applied for an emergency license in the USA.
It should be noted that if this formulation is approved, it will be the first licensed antiviral drug for COVID-19 to be taken. from the mouth.
“It simply came to our notice then. We need to see the full details of this. If true, then this is another one weapon in the fight against the COVID-19 pandemic “, answered the representative of the WHO Christian Lindmeier when asked at a press conference in Geneva about the drug.
As broadcast by ΑΠΕ ΜΠΕ, the molnupiravir, Merck antiviral pill, reduced by 50% the rate of hospitalization and death from COVID-19 in a trial performed in patients with mild to moderate symptoms of the disease who had at least one risk factor for the disease, according to data released this month.
Merck expects to produce 10 million therapeuticshapes by the end of 2021, while more are expected to be produced in 2022, according to the company.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
